Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Forbes

Showing results (21-30 of 85) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|December 16, 2014
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trialJack Cuzick, Ivana Sestak, Simon Cawthorn, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 12, 2015
Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment optionsJanine M Lombard, Nicholas Zdenkowski, Kathy Wells, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Improving informed consent in clinical trials: successful piloting of a decision aidIlona Juraskova, Phyllis Butow, Anna-Lena Lopez, et al.
The Lancet. Oncology|August 16, 2008
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysisIvana Sestak, Jack Cuzick, Francisco Sapunar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trialAlistair Ring, Ivana Sestak, Michael Baum, et al.
Scientific Reports|November 6, 2015
Novel genes associated with lymph node metastasis in triple negative breast cancerAndrea Mathe, Michelle Wong-Brown, Brianna Morten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2015
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast CancerMitch Dowsett, Ivana Sestak, Richard Buus, et al.
Journal of the National Cancer Institute|April 13, 2011
Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control studyJack Cuzick, Jane Warwick, Elizabeth Pinney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2011
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factorsGong Tang, Jack Cuzick, Joseph P Costantino, et al.
Journal of Vascular Surgery|May 4, 2010
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A description of the severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic Inter-Society Consensus II classificationAndrew W Bradbury, Donald J Adam, Jocelyn Bell, et al.
Pageof 9

Showing results (21-30 of 85) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|December 16, 2014
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trialJack Cuzick, Ivana Sestak, Simon Cawthorn, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 12, 2015
Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment optionsJanine M Lombard, Nicholas Zdenkowski, Kathy Wells, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Improving informed consent in clinical trials: successful piloting of a decision aidIlona Juraskova, Phyllis Butow, Anna-Lena Lopez, et al.
The Lancet. Oncology|August 16, 2008
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysisIvana Sestak, Jack Cuzick, Francisco Sapunar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trialAlistair Ring, Ivana Sestak, Michael Baum, et al.
Scientific Reports|November 6, 2015
Novel genes associated with lymph node metastasis in triple negative breast cancerAndrea Mathe, Michelle Wong-Brown, Brianna Morten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2015
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast CancerMitch Dowsett, Ivana Sestak, Richard Buus, et al.
Journal of the National Cancer Institute|April 13, 2011
Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control studyJack Cuzick, Jane Warwick, Elizabeth Pinney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2011
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factorsGong Tang, Jack Cuzick, Joseph P Costantino, et al.
Journal of Vascular Surgery|May 4, 2010
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A description of the severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic Inter-Society Consensus II classificationAndrew W Bradbury, Donald J Adam, Jocelyn Bell, et al.
Pageof 9